Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1021-335X Online ISSN: 1791-2431
Journal Cover
July-2014 Volume 32 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
July-2014 Volume 32 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Gallic acid inhibits migration and invasion of SCC‑4 human oral cancer cells through actions of NF‑κB, Ras and matrix metalloproteinase-2 and -9

  • Authors:
    • Chao-Lin Kuo
    • Kuang-Chi Lai
    • Yi-Shih Ma
    • Shu-Wen Weng
    • Jing-Pin Lin
    • Jing-Gung Chung
  • View Affiliations / Copyright

    Affiliations: Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan, R.O.C., Department of Medicine, China Medical University, Taichung, Taiwan, R.O.C., School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan, R.O.C., Graduate Institute of Chinese Medicine, China Medical University, Taichung, Taiwan, R.O.C., School of Chinese Medicine, China Medical University, Taichung, Taiwan, R.O.C., Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.
  • Pages: 355-361
    |
    Published online on: May 23, 2014
       https://doi.org/10.3892/or.2014.3209
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Oral cancer is one of the major causes of mortality in humans and squamous cell carcinoma is the most common type of oral cancer. Gallic acid (GA) is a natural product that induces cell death through cell cycle arrest and induction of apoptosis. There is no available information on whether GA affects cell migration and invasion of human oral cancer cells. We determined if GA inhibited migration and invasion of SCC-4 (human squamous cell carcinoma) human oral cancer cells. GA significantly inhibited migration and invasion of SCC-4 cells based on results from the wound healing assay and Matrigel Cell Migration Assay and Invasion System. We also showed that GA significantly inhibited matrix metalloproteinase (MMP)-2 and MMP-9 activity. GA reduced protein levels of FAK, MEKK3, p-PERK, p-p38, p-JNK1/2, p-ERK1/2, SOS1, RhoA, Ras, PKC, p-AKT(Thr308), PI3K, NF-κB p65, MMP-2 and MMP-9 in SCC-4 cells. Translocation of NF-κB and RhoA from the cytosol to the nucleus was reduced by GA in SCC-4 cells. In summary, GA inhibits migration and invasion of SCC-4 cells by inhibiting NF-κB expression causing suppression of MMP-2 and MMP-9 activity. GA may have potential as a therapeutic agent for the treatment of oral cancer.

Introduction

Squamous cell carcinoma (SCC) accounts for ~90% of oral cancers (1); it is the sixth most common malignancy in the world (2) and one of the leading causes of cancer-related mortality (3,4). In Taiwan, based on a 2012 report from the Department of Health, R.O.C. (Taiwan), ~11.0 individuals per 10,000 die annually from oral cancer. In Taiwan, oral cancer is the fourth most common cancer in men and the 16th in women. There are several different treatments for oral cancer (including surgery, radiation and chemotherapy); however, the overall survival rate is unsatisfactory (4). A challenge to cancer treatment is that cancer cells migrate to and invade other tissues or organs. There is a need to find new agents to treat SCC.

Gallic acid (3,4,5-trihydroxybenzoic acid; GA) exists in natural plants and has been shown to have anticancer effects in human leukemia HL-60RG (5), lung cancer (6), stomach cancer, colon cancer (7), prostate cancer (8,9), melanoma (10) and esophageal cancer (11), PC12 rat pheochromocytoma (12) and mouse leukemia WEHI-3 cells (13). Our laboratory previously reported that GA induces apoptosis in human lung cancer NCI-H460 cells in vitro and in vivo (14). Cancer metastasis is caused by cell adhesion, migration and invasion. GA has anti-metastatic effects on gastric cancer cells which is due to inhibition of NF-κB activity and downregulation of PI3K/AKT/small GTPs signaling (15). GA inhibits the migration and invasion of A375.S2 human melanoma cells through the inhibition of matrix metalloproteinase (MMP)-2 and Ras (16), and GA inhibits adhesion of melanoma B16F10 cells (14). Recently, we also found that GA-inhibited migration and invasion in U-2 OS cells that may be due to downregulation of PKC, inhibition of mitogen-activated protein kinase (MAPK) and PI3K/AKT, resulting in inhibition of MMP-2 and MMP-9 expression (17). There are no reports on whether GA blocks migration and invasion of human oral cancer cells. In the present study, we determined whether GA inhibits migration and invasion of human oral cancer SCC-4 cells in vitro.

Materials and methods

Materials and chemicals

GA, dimethyl sulfoxide (DMSO), pyruvate, penicillin G, streptomycin, trypan blue and Triton X-100 were purchased from Sigma Chemical. (St. Louis, MO, USA). Primary and secondary antibodies for western blotting were purchased from Biotechnology (Santa Cruz, CA, USA). Materials and chemicals for electrophoresis were obtained from Bio-Rad (Hercules, CA, USA).

SCC-4 cell culture

The SCC-4 human oral cell line was purchased from the Food Industry Research and Development Institute (Hsinchu, Taiwan). Cells were cultured in 90% DMEM medium with 10% FBS and 2 mM L-glutamine containing antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin). Cells were cultured in 75-cm2 tissue culture flasks and incubated under a humidified 5% CO2 atmosphere at 37°C as previously described (18).

Cell viability assay

SCC-4 cells (2×105 cells/well) were maintained in 12-well plates for 24 h. Cells were then incubated with 0, 5, 30 and 60 μM of GA for 24 and 48 h. Each treatment was performed in triplicate. Cells were harvested and PI (5 μg/ml) added to the cells and analyzed using a PI exclusion method by flow cytometry (BD Biosciences, FACSCalibur, San Jose, CA, USA) as previously described (18,19).

Cell-matrix adhesion assay

SCC-4 cells (2×105 cells/well) were maintained in 12-well plates and were then incubated with 0, 5, 30 and 60 μM of GA for 24 and 48 h. Cells were then placed on 24-well plates which were coated with 150 μl of 10 μg/ml type I collagen for 2 h. Non-adherent cells were removed and adherent cells were fixed with ethanol for 15 min and then stained with 0.2% crystal violet for 10 min and washed with PBS. Cells were lysed in 0.2% Triton X-100 for 30 min and 150 μl of the lysate was added to a 96-well ELISA plate. The absorbance (540 nm) was measured as described previously (19).

Wound healing assay

SCC-4 cells (5×105 cells/well) were kept in 10-cm Petri dishes for 24 h. Wounds were created with a sterile yellow micropipette tip on cell monolayers. Unscraped cells were washed with PBS three times and dead cells removed and fresh DMEM medium supplemented with FBS containing 0, 5, 30 and 60 μM of GA added for 24 h. The wound healing area was then examined and images were captured using an inverted microscope as described previously (18,19).

Cell migration and invasion assays

Matrigel Cell Migration Assay and Invasion System were used for measuring cell migration and invasion, respectively, as described previously (18). The cell migration assay was performed using Transwell cell culture chambers (8-mm pore size; Millipore, Billerica, MA, USA). SCC-4 cells (5×104 cells/well) were added to serum-free DMEM medium and placed in the upper chamber of the Transwell insert and incubated with 0, 30 and 60 μM of GA. DMEM medium (90%) containing 10% FBS was added to the lower chamber as a chemoattractant. Following incubation for 24 and 48 h, non-migrating cells were removed from the top chamber with a cotton swab. The cells on the lower surface were fixed with 4% formaldehyde in PBS. At the end of fixation, the chambers were rinsed with PBS and cells in the lower chamber were stained with 2% crystal violet in 2% ethanol for 10 min. Images were counted and captured using a light microscope at ×200. The cell invasion assay was performed the same as the cell migration assay except that the filter membrane was coated with Matrigel from a BioCoat Matrigel invasion kit. Cells that invaded to the underside of the filter were counted using a light microscope at ×200 as described previously (18,19).

Gelatin gel zymographic assay for MMP-2 activity

Gelatin gel zymography was used to quantify MMP-2 activity according to the manufacturer’s instructions. Briefly, SCC-4 cells (5×105 cells/well) were maintained in 12-well plates and then treated with GA (0, 5, 30 and 60 μM) for 24 and 48 h. Total protein (50 μg) was re-suspended in non-reducing loading buffer and incubated at 37°C for 15 min. Electrophoresis was performed on 10% SDS-PAGE cast with 0.1% gelatin and electrophoresed on Novex® Zymogram gels (Life Technologies). The specific MMP-2 bands were detected by staining with Coomassie Brilliant Blue (Life Technologies) as described previously (18,19).

Western blot analysis of proteins associated with cell migration and invasion

SCC-4 cells (1×106 cells/well) were placed in 6-well plates for 24 h and were then incubated with 0, 5, 30 and 60 μM of GA for 0, 24 and 48 h. Cells were harvested, lysed, and total protein determined by a Bio-Rad protein assay kit (Hercules, CA, USA) with bovine serum albumin (BSA) as the standard as described previously (18,19). Samples (30 μg protein) were loaded onto 12% SDS-polyacrylamide gels, electrophoresed and then electrotransferred to nitrocellulose membranes, blotted with the relevant primary antibodies [anti-FAK, MEKK3, p-PERK, p-p38, p-JNK1/2, p-ERK1/2, SOS1, RhoA, GRB2, Ras, PKC, p-AKT (Thr308), PI3K, NF-κB p65, MMP-2 and MMP-9], washed, and then stained with a secondary antibody. Protein bands were examined by an enhanced chemiluminescence reagent (ECLTM; Amersham Biosciences) and bands were quantified using an NIH Image analyzer (NIH, Bethesda, MD, USA) as described previously (18,19).

Immunofluorescence staining and confocal laser scanning microscopy

SCC-4 cells (3×105 cells/well) were plated on 6-well chamber slides, treated with 0, 30 and 60 μM of GA for 24 h, and fixed with formaldehyde (3%) in PBS for 15 min. The cells were permeabilized using 0.1% Triton X-100 in PBS for 1 h and washed three times with PBS followed by blocking of SCC-4 cells (3×105 cells/well) using 2% BSA in non-specific binding sites as described previously (18). Cells were stained with primary antibodies such as anti-NF-κB p65 and RhoA (1:100 dilution) overnight, and were then stained with secondary FITC-conjugated goat anti-mouse IgG (1:200 dilution) (green fluorescence). Cell nuclei were counterstained with PI (Molecular Probes; Invitrogen Corp.) (red fluorescence). All samples were photomicrographed using a Leica TCS SP2 confocal spectral microscope as described previously (18,19).

Statistical analysis

All experiments were performed in triplicate and data are expressed as mean ± SD. Statistical analysis was carried out using Student’s t-test, with values of *P<0.05 considered to indicate statistically significant differences.

Results

GA decreases the percentage of viable SCC-4 human oral cancer cells

We evaluated the effects of GA on cell viability using flow cytometry and results are shown in Fig. 1. GA at concentrations of 5–60 μM significantly reduced cell viability in a dose and time-dependent manner (Fig. 1).

Figure 1

Gallic acid (GA) decreases the percentage of viable SCC-4 human oral cancer cells. Cells (2×105 cells/well) were incubated with 0, 5, 30 and 60 μM of GA for 24 and 48 h and were then harvested for measuring the percentage of viable cells by flow cytometry as described in Materials and methods. *P<0.05, significant difference between GA-treated and control groups as analyzed by Student’s t-test.

GA inhibits the adhesion of SCC-4 cells in vitro

SCC-4 cells were treated with 0, 5, 30 and 60 μM GA and inhibition of cell adhesion was determined using an ELISA reader. Results are shown in Fig. 2A and B. Cell adhesion was significantly reduced dose- and time-independently by GA compared with control groups.

Figure 2

Gallic acid (GA) inhibits the cell-matrix adhesion of SCC-4 cells. SCC-4 cells (2×105 cells/well) were incubated with 0, 5, 30 and 60 μM of GA for (A) 24 and (B) 48 h. All cells were placed on 24-well plates which were coated with 150 μl of type I collagen for 2 h. Then adherent cells were fixed with ethanol for 15 min and were stained with 0.2% crystal violet for 10 min. Cells were lysed in 0.2% Triton X-100 for 30 min and the 150 μl lysed solution was individually added to a 96-well ELISA plate, followed by measurement of the 540 nm absorbance as described in Materials and methods. *P<0.05, significant difference between GA-treated and control groups as analyzed by Student’s t-test.

GA suppresses the migration of SCC-4 cells in vitro

SCC-4 cells were treated with 0, 5, 30 and 60 μM of GA and wound healing assay performed. Data in Fig. 3 show that GA inhibited the migration of SCC-4 cells based on the extent of wound closure. These effects were dose- and time-dependent.

Figure 3

Gallic acid (GA) affects the migration of SCC-4 cell. Cells were kept on the 6-well dish for 24 h and then a wound was created by a yellow pipette tip to scrape the confluent cell layers. GA (0, 5, 30, and 60 μM) was individually added to the well and was then incubated for 24 h. Some of the representative images of invading treated and untreated cells are presented.

GA inhibits the migration and invasion of SCC-4 cells in vitro

Cell migration activity and invasion potential of SCC-4 cells were examined and photographed and the representative figures and evaluated inhibitions are shown in Fig. 4. Fig. 4A and B indicate that GA significantly inhibited migration of SCC-4 cells, ratio of migrated cells went from 50.56 to 36.81% treated with 30 and 60 μM respectively at 24 h, to 66.40 and 51.99% at 48 h. This was in agreement with results from the healing assay (Fig. 3). Fig. 4C and D indicate that GA significantly inhibited the invasion of SCC-4 cells, ratio of invaded cells went from 53.18 to 40.17% treated with 30 and 60 μM respectively at 24 h, to 65.67 and 54.74 % at 48 h.

Figure 4

Gallic acid (GA) suppresses the migration and invasion of SCC-4 cells in vitro. Cells (5×104 cells/well) were treated with or without GA for 24 h after cells penetrated through to the lower surface of the filter, without Matrigel for migration examination (A and B), with Matrigel for invasion examination (C and D). They were then stained with crystal violet, examined and images were captured under a light microscope at ×200. Quantification of cells in the lower chambers was performed by counting cells at ×200. Representative columns (mean) from three independent experiments. *P<0.05, significant difference between GA-treated groups and the control as analyzed by Student’s t-test.

GA inhibits MMP-2 activity of SCC-4 cells

Effects of GA on MMP-2 activity were determined using gelatin zymography. As shown in Fig. 5, SCC-4 cells constitutively secreted high levels of MMP-2 but when incubated with GA at 5, 30 and 60 μM for 24 and 48 h, MMP-2 activity was significantly reduced. This effect of GA was dose-dependent (Fig. 5).

Figure 5

Gallic acid (GA) affects the activities of matrix metalloproteinase (MMP) activities in SAS cells. Cells were treated with or without GA at the final concentration of 0, 5, 30 and 60 μM and were then harvested and performed by gelatin zymography. Representative zymogram from three independent experiments was used to detect the activity of secreted MMP-2. The different activities of MMP-2 were determined by densitometric analysis and results are expressed as a percentage of the control (100%).

GA alters levels of proteins associated with migration and invasion of SCC-4 cells

MMP-2 and MMP-9 are potential target molecules for anti-metastatic activity, and we investigated the effects of GA on MMP-2 and MMP-9 and associated signal protein levels in SCC-4 cells. GA markedly reduced protein levels of FAK, MEKK3, p-PERK (Fig. 6A), p-p38, p-JNK1/2, p-ERK1/2 (Fig. 6B) and SOS1, RhoA, Ras (Fig. 6C). It was also observed that protein levels of PKC, p-AKT (Thr308), PI3K, (Fig. 6D) were decreased in GA-treated cells compared with control cells.

Figure 6

Gallic acid (GA) affects the levels of associated proteins in migration and invasion of SCC-4 cells. Cells (5×104 cells/well) were treated with 5, 30 and 60 μM of GA for 24 and 48 h and then cells were collected for the total protein extracted and determined as described in Materials and methods. The levels of FAK, MEKK3, PERK (A); p38, JNK1/2, ERK1/2 (B); SOS1, RhoA, GRB2, Ras (C); PKC, p-AKT(Thr308), PI3K (D); NF-κB p65 (E); MMP-2, MMP-9 (F) expression were estimated by western blotting as described in Materials and methods.

GA alters translocation of NF-κB and RhoA in SCC-4 cells

Effects of GA on distribution of NF-κB p65 and RhoA in SCC-4 cells were examined by confocal laser system microscopy and results can be seen in Fig. 7A and B. GA inhibited the NF-κB p65 (Fig. 7A) and RhoA (Fig. 7B) protein levels in cytosol but increased the protein levels in nuclei.

Figure 7

Gallic acid (GA) affects the NF-κB p65 and RhoA translocation in SCC-4 cells. Cells (5×104 cells/well) were placed on 6-well chamber slides and were then treated with 30 and 60 μM of GA for 24 h. They were then fixed and stained using anti-NF-κB p65 (A), RhoA (B) antibodies (1:100) and stained with a secondary antibody (green fluorescence) followed by nuclear counterstaining with PI (red fluorescence). Photomicrographs were obtained using a Leica TCS SP2 confocal spectral microscope as described in Materials and methods.

Discussion

Numerous studies have demonstrated that gallic acid (GA) induces cytotoxic effects through cell cycle arrest and induction of apoptosis in many human cancer cell lines. There are a few reports showing GA inhibited metastasis of cancer cells (15–18). However, the effects of GA on the cell motility of human oral cancer SCC-4 cells have not been examined. We investigated the effects of GA on the migration and invasion of SCC-4 cells in vitro. GA inhibited migration and invasion and these effects were associated with MMP-2 and MMP-9 activity and other specific proteins (NF-κB p65, RhoA). MMP-2 and MMP-9 play a critical role in cancer cell migration and invasion (20,21) and overexpression of both enzymes increases migration and invasion of cancer cells (22,23). In the present study, we showed that GA markedly inhibited activation status of MMP-2 and MMP-9 using gelatin zymography (Fig. 5). These findings were consistent with our data showing that GA decreased the protein levels of MMP-2 and MMP-9 (Fig. 7F). GA also reduced protein levels of PI-3K and downstream kinases JNK and p-p38 (Fig. 7B), and NF-κB (Fig. 7E) in SCC-4 cells. These findings are in agreement with another report which found that GA blocked cell migration and invasion which was associated with inhibition of NF-κB and downregulation of PI3K and AKT signaling (15). It is well documented that NF-κB acts on downstream proteins such as MMP-2 and MMP-9 (24,25).

GA inhibited the translocation of NF-κB from the cytosol to the nucleus (Fig. 7A) and significantly reduced protein levels of FAK, MEEK3 and p-PERK in SCC-4 cells. Earlier reports indicated that FAK/Scr was associated with tumor cell migration and invasion (24,25). Activated FAK (Tyr 397)/Src (Tyr 416) may act on PI-3K/AKT and Ras/ERK1/2 cascades impacting signaling (26,27). It was reported that FAK/Src complex allows Src to phosphorylate FAK and then to interact with GRB2 and activation of the Ras-ERK signaling pathway (28).

GA in the present study inhibited the expression of RhoA in SCC-4 cells. RhoA belongs to the prototype protein of the Rho GTPase superfamily that is associated with cell migration among its many effects (28). Both RhoA and ROCK1 are upregulated in tumors and are predicative of cancer progression, metastasis and poor prognosis (29,30). Inhibition of the RhoA/ROCK1 pathway leads to tumor cell death and reduced metastasis (31,32). The RhoA/ROCK1 pathway may be a promising target for cancer therapy in the future and further investigation is required.

We found that GA inhibited protein levels of Ras and SOS-1 but increased GRB2 abundance (Fig. 7C) in SCC-4 cells. Numerous studies have demonstrated that Grb2 (33), Ras (34), and PKC (35,36) are involved in cell mobility. GA inhibition of cell migration and invasion of SCC-4 cells may also involve inhibition of SOS-1, Ras and RhoA. As depicted in Fig. 8, we propose that GA inhibition of SCC-4 cell migration and invasion may occur via regulation of PKC, Ras, SOS1, FAK, p-JNK1/2, p-ERK1/2, p-p38, PI3K, p-AKT and NF-κB expression. A major consequence of these effects is inhibition of MMP-2 and MMP-9 activity and protein signaling pathways.

Figure 8

The possible signaling pathways for gallic acid-inhibited cell migration and invasion in SCC-4 human oral cancer cells.

Acknowledgements

This study was supported by grant DOH99-TD-C-111-005 from Department of Health, Executive Yuan (Taiwan, R.O.C). Experiments and data analysis were performed in part through the use of the Medical Research Core Facilities Center, Office of Research and Development at China Medical University, Taichung, Taiwan, R.O.C.

References

1 

Castro TP and Bussoloti Filho I: Prevalence of human papillomavirus (HPV) in oral cavity and oropharynx. Braz J Otorhinolaryngol. 72:272–282. 2006.PubMed/NCBI

2 

Lingen MW, Pinto A, Mendes RA, et al: Genetics/epigenetics of oral premalignancy: current status and future research. Oral Dis. 17(Suppl 1): 7–22. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Scully C and Bagan J: Oral squamous cell carcinoma overview. Oral Oncol. 45:301–308. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar

5 

Inoue M, Suzuki R, Koide T, Sakaguchi N, Ogihara Y and Yabu Y: Antioxidant, gallic acid, induces apoptosis in HL-60RG cells. Biochem Biophys Res Commun. 204:898–904. 1994. View Article : Google Scholar : PubMed/NCBI

6 

You BR, Kim SZ, Kim SH and Park WH: Gallic acid-induced lung cancer cell death is accompanied by ROS increase and glutathione depletion. Mol Cell Biochem. 357:295–303. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Yoshioka K, Kataoka T, Hayashi T, Hasegawa M, Ishi Y and Hibasami H: Induction of apoptosis by gallic acid in human stomach cancer KATO III and colon adenocarcinoma COLO 205 cell lines. Oncol Rep. 7:1221–1223. 2000.PubMed/NCBI

8 

Veluri R, Singh RP, Liu Z, Thompson JA, Agarwal R and Agarwal C: Fractionation of grape seed extract and identification of gallic acid as one of the major active constituents causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells. Carcinogenesis. 27:1445–1453. 2006. View Article : Google Scholar

9 

Raina K, Rajamanickam S, Deep G, Singh M, Agarwal R and Agarwal C: Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice. Mol Cancer Ther. 7:1258–1267. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Locatelli C, Leal PC, Yunes RA, Nunes RJ and Creczynski-Pasa TB: Gallic acid ester derivatives induce apoptosis and cell adhesion inhibition in melanoma cells: the relationship between free radical generation, glutathione depletion and cell death. Chem Biol Interact. 181:175–184. 2009. View Article : Google Scholar

11 

Faried A, Kurnia D, Faried LS, et al: Anticancer effects of gallic acid isolated from Indonesian herbal medicine, Phaleria macrocarpa (Scheff.) Boerl, on human cancer cell lines. Int J Oncol. 30:605–613. 2007.PubMed/NCBI

12 

Kang MK, Kang NJ, Jang YJ, Lee KW and Lee HJ: Gallic acid induces neuronal cell death through activation of c-Jun N-terminal kinase and downregulation of Bcl-2. Ann NY Acad Sci. 1171:514–520. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Serrano A, Palacios C, Roy G, et al: Derivatives of gallic acid induce apoptosis in tumoral cell lines and inhibit lymphocyte proliferation. Arch Biochem Biophys. 350:49–54. 1998. View Article : Google Scholar : PubMed/NCBI

14 

Ji BC, Hsu WH, Yang JS, et al: Gallic acid induces apoptosis via caspase-3 and mitochondrion-dependent pathways in vitro and suppresses lung xenograft tumor growth in vivo. J Agric Food Chem. 57:7596–7604. 2009. View Article : Google Scholar : PubMed/NCBI

15 

Ho HH, Chang CS, Ho WC, Liao SY, Wu CH and Wang CJ: Anti-metastasis effects of gallic acid on gastric cancer cells involves inhibition of NF-kappaB activity and downregulation of PI3K/AKT/small GTPase signals. Food Chem Toxicol. 48:2508–2516. 2010. View Article : Google Scholar

16 

Lo C, Lai TY, Yang JS, et al: Gallic acid inhibits the migration and invasion of A375.S2 human melanoma cells through the inhibition of matrix metalloproteinase-2 and Ras. Melanoma Res. 21:267–273. 2011. View Article : Google Scholar : PubMed/NCBI

17 

Liao CL, Lai KC, Huang AC, et al: Gallic acid inhibits migration and invasion in human osteosarcoma U-2 OS cells through suppressing the matrix metalloproteinase-2/-9, protein kinase B (PKB) and PKC signaling pathways. Food Chem Toxicol. 50:1734–1740. 2012. View Article : Google Scholar

18 

Lai WW, Hsu SC, Chueh FS, et al: Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-κB and matrix metalloproteinase-2/-9 signaling pathways. Anticancer Res. 33:1941–1950. 2013.PubMed/NCBI

19 

Liu KC, Huang AC, Wu PP, et al: Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and -9 signaling pathways. Oncol Rep. 26:177–184. 2011.PubMed/NCBI

20 

Toth M, Sohail A and Fridman R: Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Biol. 878:121–135. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Sangle NA and Layfield LJ: Telangiectatic osteosarcoma. Arch Pathol Lab Med. 136:572–576. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Shi GZ, Yuan Y, Jiang GJ, et al: PRAF3 induces apoptosis and inhibits migration and invasion in human esophageal squamous cell carcinoma. BMC Cancer. 12:972012. View Article : Google Scholar : PubMed/NCBI

23 

Chen K, Zhang S, Ji Y, et al: Baicalein inhibits the invasion and metastatic capabilities of hepatocellular carcinoma cells via down-regulation of the ERK pathway. PLoS One. 8:e729272013. View Article : Google Scholar : PubMed/NCBI

24 

Shen J, Xu L, Owonikoko TK, et al: NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKCι/FAK loop. Cancer Lett. 318:106–113. 2012.PubMed/NCBI

25 

Bianchi-Smiraglia A, Paesante S and Bakin AV: Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene. 32:3049–3058. 2013.

26 

Mamali I, Tatari MN, Micheva I, Lampropoulou M and Marmaras VJ: Apoptosis in medfly hemocytes is regulated during pupariation through FAK, Src, ERK, PI-3K p85a, and Akt survival signaling. J Cell Biochem. 101:331–347. 2007. View Article : Google Scholar : PubMed/NCBI

27 

Arpaia E, Blaser H, Quintela-Fandino M, et al: The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene. 31:884–896. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Bolos V, Gasent JM, Lopez-Tarruella S and Grande E: The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther. 3:83–97. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Karlsson R, Pedersen ED, Wang Z and Brakebusch C: Rho GTPase function in tumorigenesis. Biochim Biophys Acta. 1796:91–98. 2009.PubMed/NCBI

30 

Li F, Jiang Q, Shi KJ, Luo H, Yang Y and Xu CM: RhoA modulates functional and physical interaction between ROCK1 and Erk1/2 in selenite-induced apoptosis of leukaemia cells. Cell Death Dis. 4:e7082013. View Article : Google Scholar : PubMed/NCBI

31 

Fromigue O, Haÿ E, Modrowski D, et al: RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 13:1845–1856. 2006. View Article : Google Scholar : PubMed/NCBI

32 

Lochhead PA, Wickman G, Mezna M and Olson MF: Activating ROCK1 somatic mutations in human cancer. Oncogene. 29:2591–2598. 2010. View Article : Google Scholar : PubMed/NCBI

33 

Tsai NP and Wei LN: RhoA/ROCK1 signaling regulates stress granule formation and apoptosis. Cell Signal. 22:668–675. 2010. View Article : Google Scholar : PubMed/NCBI

34 

Lee SH, Jeong EG, Nam SW, Lee JY, Yoo NJ and Lee SH: Increased expression of Gab2, a scaffolding adaptor of the tyrosine kinase signalling, in gastric carcinomas. Pathology. 39:326–329. 2007. View Article : Google Scholar : PubMed/NCBI

35 

Zhang J, Anastasiadis PZ, Liu Y, Thompson EA and Fields AP: Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J Biol Chem. 279:22118–22123. 2004. View Article : Google Scholar : PubMed/NCBI

36 

Lawler K, Foran E, O’Sullivan G, Long A and Kenny D: Mobility and invasiveness of metastatic esophageal cancer are potentiated by shear stress in a ROCK- and Ras-dependent manner. Am J Physiol Cell Physiol. 291:C668–C677. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Kuo C, Lai K, Ma Y, Weng S, Lin J and Chung J: Gallic acid inhibits migration and invasion of SCC‑4 human oral cancer cells through actions of NF‑κB, Ras and matrix metalloproteinase-2 and -9. Oncol Rep 32: 355-361, 2014.
APA
Kuo, C., Lai, K., Ma, Y., Weng, S., Lin, J., & Chung, J. (2014). Gallic acid inhibits migration and invasion of SCC‑4 human oral cancer cells through actions of NF‑κB, Ras and matrix metalloproteinase-2 and -9. Oncology Reports, 32, 355-361. https://doi.org/10.3892/or.2014.3209
MLA
Kuo, C., Lai, K., Ma, Y., Weng, S., Lin, J., Chung, J."Gallic acid inhibits migration and invasion of SCC‑4 human oral cancer cells through actions of NF‑κB, Ras and matrix metalloproteinase-2 and -9". Oncology Reports 32.1 (2014): 355-361.
Chicago
Kuo, C., Lai, K., Ma, Y., Weng, S., Lin, J., Chung, J."Gallic acid inhibits migration and invasion of SCC‑4 human oral cancer cells through actions of NF‑κB, Ras and matrix metalloproteinase-2 and -9". Oncology Reports 32, no. 1 (2014): 355-361. https://doi.org/10.3892/or.2014.3209
Copy and paste a formatted citation
x
Spandidos Publications style
Kuo C, Lai K, Ma Y, Weng S, Lin J and Chung J: Gallic acid inhibits migration and invasion of SCC‑4 human oral cancer cells through actions of NF‑κB, Ras and matrix metalloproteinase-2 and -9. Oncol Rep 32: 355-361, 2014.
APA
Kuo, C., Lai, K., Ma, Y., Weng, S., Lin, J., & Chung, J. (2014). Gallic acid inhibits migration and invasion of SCC‑4 human oral cancer cells through actions of NF‑κB, Ras and matrix metalloproteinase-2 and -9. Oncology Reports, 32, 355-361. https://doi.org/10.3892/or.2014.3209
MLA
Kuo, C., Lai, K., Ma, Y., Weng, S., Lin, J., Chung, J."Gallic acid inhibits migration and invasion of SCC‑4 human oral cancer cells through actions of NF‑κB, Ras and matrix metalloproteinase-2 and -9". Oncology Reports 32.1 (2014): 355-361.
Chicago
Kuo, C., Lai, K., Ma, Y., Weng, S., Lin, J., Chung, J."Gallic acid inhibits migration and invasion of SCC‑4 human oral cancer cells through actions of NF‑κB, Ras and matrix metalloproteinase-2 and -9". Oncology Reports 32, no. 1 (2014): 355-361. https://doi.org/10.3892/or.2014.3209
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team